FibroGen Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia … – Business Wire (press release)
FibroGen Reports Dose-finding Data from Phase 2b Study of FG-4592 for Anemia …Business Wire (press release)… dose-finding study of FG-4592, an investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), for anemia correction …